Equities researchers at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Trading Down 5.5 %
NASDAQ PULM opened at $2.05 on Monday. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $2.75. The company has a market capitalization of $7.49 million, a price-to-earnings ratio of -0.85 and a beta of 0.99. The stock’s 50 day moving average is $2.10 and its two-hundred day moving average is $1.98.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The company had revenue of $1.55 million during the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- 3 Stocks to Consider Buying in October
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Following Congress Stock Trades
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Stock Sentiment Analysis: How it Works
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
